PDF(Pubmed)
Abstract：
BACKGROUND: Peganum harmala L. is used in traditional medicine to treat several health ailments. Hence, the present work aimed to investigate the DPPH free radical scavenging, α-amylase, cytotoxic, and antifibrotic effects of the hydrophilic extract and fixed oil obtained from P. harmala seeds.
METHODS: The hydrophilic extract and fixed oil of P. harmala were assessed for their abilities to scavenge DPPH free radicals and inhibit α-amylase using reference bioassays. The cytotoxicity was assessed on several cancer and normal cell lines, including B16F1, Caco-2, COLO205, HeLa, Hep 3B and Hep G2, MCF-7, and HEK-293 T cells. The MTS assay was used to evaluate the antifibrotic capabilities utilizing the human hepatic stellate (LX-2) cell line.
RESULTS: P. harmala plant fixed oil has potent DPPH free radical scavenging activity with an IC50 dose of 79.43 ± 0.08 µg/ml. Besides, the hydrophilic extract has a poor anti-α-amylase effect compared with the antidiabetic drug Acarbose, with IC50 doses of 398 ± 0.59 and 25.11 ± 1.22 µg/ml, respectively. In addition, the growth of MCF-7, Hep3B, HepG2, HeLa, COLO205, CaCo2, B16F1, and HeK293t was inhibited by P. harmala hydrophilic extract with IC50 doses of 121.34 ± 1.71, 268.3 ± 0.75, 297.20 ± 1.00, 155.60 ± 1.14, 150.01 ± 0.51, 308.35 ± 0.53, 597.93 ± 1.36, and 5.38 ± 0.99 µg/ml, respectively. In addition, at 1000 µg/ml, 5-Fluorouracil reduced fibrosis cells by 0.089%, while the hydrophilic extract decreased the number of LX-2 cells by 5.81%.
CONCLUSIONS: P. harmala plant-fixed oil exhibits potential antioxidant properties. While the hydrophilic extract showed limited effectiveness as an anti-α-amylase agent and demonstrated notable cytotoxic effects against various tested cancer cell lines. Furthermore, this extract significantly reduces the number of LX-2 fibrotic cells. These findings emphasize the therapeutic potential of these products in managing various health disorders and warrant further investigation into their mechanisms of action and clinical applications.
METHODS: The hydrophilic extract and fixed oil of P. harmala were assessed for their abilities to scavenge DPPH free radicals and inhibit α-amylase using reference bioassays. The cytotoxicity was assessed on several cancer and normal cell lines, including B16F1, Caco-2, COLO205, HeLa, Hep 3B and Hep G2, MCF-7, and HEK-293 T cells. The MTS assay was used to evaluate the antifibrotic capabilities utilizing the human hepatic stellate (LX-2) cell line.
RESULTS: P. harmala plant fixed oil has potent DPPH free radical scavenging activity with an IC50 dose of 79.43 ± 0.08 µg/ml. Besides, the hydrophilic extract has a poor anti-α-amylase effect compared with the antidiabetic drug Acarbose, with IC50 doses of 398 ± 0.59 and 25.11 ± 1.22 µg/ml, respectively. In addition, the growth of MCF-7, Hep3B, HepG2, HeLa, COLO205, CaCo2, B16F1, and HeK293t was inhibited by P. harmala hydrophilic extract with IC50 doses of 121.34 ± 1.71, 268.3 ± 0.75, 297.20 ± 1.00, 155.60 ± 1.14, 150.01 ± 0.51, 308.35 ± 0.53, 597.93 ± 1.36, and 5.38 ± 0.99 µg/ml, respectively. In addition, at 1000 µg/ml, 5-Fluorouracil reduced fibrosis cells by 0.089%, while the hydrophilic extract decreased the number of LX-2 cells by 5.81%.
CONCLUSIONS: P. harmala plant-fixed oil exhibits potential antioxidant properties. While the hydrophilic extract showed limited effectiveness as an anti-α-amylase agent and demonstrated notable cytotoxic effects against various tested cancer cell lines. Furthermore, this extract significantly reduces the number of LX-2 fibrotic cells. These findings emphasize the therapeutic potential of these products in managing various health disorders and warrant further investigation into their mechanisms of action and clinical applications.
摘要：
背景：在传统医学中使用小至门治疗几种健康疾病。因此，本工作旨在研究DPPH自由基的清除，α-淀粉酶,细胞毒性，和从P.harmala种子获得的亲水性提取物和固定油的抗纤维化作用。
方法：使用参考生物测定法评估了P.harmala的亲水性提取物和固定油清除DPPH自由基和抑制α-淀粉酶的能力。在几种癌症和正常细胞系上评估了细胞毒性，包括B16F1,Caco-2,COLO205,HeLa,Hep3B和HepG2、MCF-7和HEK-293T细胞。MTS测定用于利用人肝星状(LX-2)细胞系评估抗纤维化能力。
结果：P.harmala植物固定油具有有效的DPPH自由基清除活性，IC50剂量为79.43±0.08µg/ml。此外,与抗糖尿病药物阿卡波糖相比，亲水性提取物的抗α-淀粉酶作用较差，IC50剂量为398±0.59和25.11±1.22µg/ml，分别。此外,MCF-7、Hep3B、HepG2,HeLa,COLO205，CaCo2，B16F1和HeK293t被P.harmala亲水提取物抑制，IC50剂量为121.34±1.71、268.3±0.75、297.20±1.00、155.60±1.14、150.01±0.51、308.35±0.53、597.93±1.36和5.38±0.99µg/ml，分别。此外,1000微克/毫升，5-氟尿嘧啶使纤维化细胞减少0.089%，而亲水性提取物使LX-2细胞数量减少了5.81%。
结论：P.harmala植物固定油具有潜在的抗氧化性能。而亲水性提取物作为抗α-淀粉酶剂显示出有限的有效性，并对各种测试的癌细胞系显示出明显的细胞毒性作用。此外，该提取物显著减少LX-2纤维化细胞的数量。这些发现强调了这些产品在管理各种健康疾病方面的治疗潜力，并需要进一步研究其作用机制和临床应用。
方法：使用参考生物测定法评估了P.harmala的亲水性提取物和固定油清除DPPH自由基和抑制α-淀粉酶的能力。在几种癌症和正常细胞系上评估了细胞毒性，包括B16F1,Caco-2,COLO205,HeLa,Hep3B和HepG2、MCF-7和HEK-293T细胞。MTS测定用于利用人肝星状(LX-2)细胞系评估抗纤维化能力。
结果：P.harmala植物固定油具有有效的DPPH自由基清除活性，IC50剂量为79.43±0.08µg/ml。此外,与抗糖尿病药物阿卡波糖相比，亲水性提取物的抗α-淀粉酶作用较差，IC50剂量为398±0.59和25.11±1.22µg/ml，分别。此外,MCF-7、Hep3B、HepG2,HeLa,COLO205，CaCo2，B16F1和HeK293t被P.harmala亲水提取物抑制，IC50剂量为121.34±1.71、268.3±0.75、297.20±1.00、155.60±1.14、150.01±0.51、308.35±0.53、597.93±1.36和5.38±0.99µg/ml，分别。此外,1000微克/毫升，5-氟尿嘧啶使纤维化细胞减少0.089%，而亲水性提取物使LX-2细胞数量减少了5.81%。
结论：P.harmala植物固定油具有潜在的抗氧化性能。而亲水性提取物作为抗α-淀粉酶剂显示出有限的有效性，并对各种测试的癌细胞系显示出明显的细胞毒性作用。此外，该提取物显著减少LX-2纤维化细胞的数量。这些发现强调了这些产品在管理各种健康疾病方面的治疗潜力，并需要进一步研究其作用机制和临床应用。
